Soligenix Inc (OQ:SNGX)
Business Focus: Bio Therapeutic Drugs
May 10, 2024 07:30 am ET
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
PRINCETON, N.J., May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2024.
May 06, 2024 07:30 am ET
Soligenix to Present at Upcoming Conferences
PRINCETON, N.J., May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below.
Apr 25, 2024 07:30 am ET
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Includes thermostabilized Ebola vaccines MarVax™ and SuVax™Includes nanoemulsion adjuvant compatible with lyophilizationPRINCETON, N.J., April 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of intent to grant additional patents based on its patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines" in the United Kingdom and
Apr 18, 2024 08:30 am ET
Soligenix Announces Pricing of $4.75 Million Public Offering
PRINCETON, N.J., April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 milli
Apr 15, 2024 07:30 am ET
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval
Apr 11, 2024 07:30 am ET
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Provides SuVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval
Apr 03, 2024 07:30 am ET
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
Feb 08, 2024 06:30 am ET
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024
Jan 26, 2024 09:00 am ET
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Jan 25, 2024 06:30 am ET
Soligenix to Present at The Microcap Conference
PRINCETON, N.J., Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at The Microcap Conference. The conference will be held January 30 and 31, and February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, N.J. For more information about The Microcap Conference, please refer to the conference website at https://themi
Jan 08, 2024 06:30 am ET
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet's Disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).
Jan 04, 2024 06:30 am ET
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Clinical Success Achieved in Second Cohort of Patients
Jan 02, 2024 06:30 am ET
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses
Dec 01, 2023 06:30 am ET
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL
Nov 30, 2023 06:30 am ET
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
Pipeline Expansion of Novel Innate Defense Regulator Technology
Nov 17, 2023 03:00 pm ET
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PRINCETON, N.J., Nov. 17, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), which was reconvened on November 16, 2023, has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange
Nov 13, 2023 06:30 am ET
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
PRINCETON, N.J., Nov. 13, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2023.
Oct 20, 2023 04:00 pm ET
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PRINCETON, N.J., Oct. 20, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), which was reconvened on October 18, 2023, has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Co
Oct 20, 2023 09:00 am ET
ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 20, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Oct 16, 2023 07:30 am ET
Soligenix to Present at The ThinkEquity Conference
PRINCETON, N.J., Oct. 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming ThinkEquity Conference. The conference will be held October 19, 2023 with presentations, one-on-one meetings, and networking. For more information about The ThinkEquity Conference, please refer to the conference website at https://www.think-equity.com/.
Oct 13, 2023 09:00 am ET
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 13, 2023 / RedChip Companies will air interviews with SPI Energy Co., Ltd., (NASDAQ:SPI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Oct 06, 2023 09:00 am ET
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show®, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Sep 25, 2023 07:30 am ET
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
Vaccines stable for at least two years when stored at 40 degrees Celsius / 104 degrees FahrenheitOnly subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and Marburg virusesNo cold chain storage and transport required as compared to other filovirus vaccinesPRINCETON, N.J., Sept. 25, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today two-year stability of its thermost
Sep 22, 2023 04:00 pm ET
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
PRINCETON, N.J., Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exch
Aug 11, 2023 10:05 am ET
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Jul 11, 2023 07:30 am ET
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
Clear biological signal demonstrated; additional patients to be enrolled
Jun 02, 2023 09:00 am ET
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / June 2, 2023 / RedChip Companies will air new interviews with Soligenix, Inc. (Nasdaq:SNGX) and Graphex Group Limited (NYSE American:GRFX) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
May 16, 2023 07:30 am ET
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims
May 15, 2023 07:30 am ET
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
PRINCETON, N.J., May 15, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2023.
May 11, 2023 07:30 am ET
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Update on FDA Meeting Outcome Expected Next Month
May 09, 2023 04:05 pm ET
Soligenix Announces Closing of $8.5 Million Public Offering
PRINCETON, N.J., May 9, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously announced public offering of 6,538,500 shares of common stock (or common stock equivalents in lieu thereof) and common warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30. The common warrants will have an exercise price of $1.50 per share, will
May 05, 2023 09:05 am ET
Soligenix Announces Pricing of $8.5 Million Public Offering
PRINCETON, N.J., May 5, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 6,538,500 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30 per share and accompanying warrant for aggregate gross proceeds of approximately $8.5 million, before
May 04, 2023 07:30 am ET
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Results Confirm and Extend Response Results from Phase 3 FLASH Study
May 03, 2023 07:30 am ET
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors
Strengthens regulatory and orphan drug development expertise
May 01, 2023 07:30 am ET
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
Phase 2/3-Ready Orphan Disease Program Complements Company's Existing Late-Stage Rare Disease Pipeline
Apr 24, 2023 07:30 am ET
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request
Apr 14, 2023 07:30 am ET
Soligenix Provides Regulatory Update on HyBryte™
PRINCETON, N.J., April 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company convened a Type A Meeting with the United States (U.S.) Food and Drug Administration (FDA). During the Type A Meeting, representatives of the Company and the FDA discussed the contents of a refusal to file (RTF) letter previously issued by the FDA regarding the Company's new drug application (NDA) for HyBr
Apr 05, 2023 07:30 am ET
Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
PRINCETON, N.J., April 5, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Adopted Names (USAN) Council has approved the use of the nonproprietary name of "hypericin sodium" for the novel active ingredient in both HyBryte™ (research name SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL) and SGX302 for the treatment of mild-to-moderate psoriasis.
Apr 03, 2023 07:30 am ET
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Update on FDA Meeting Outcome Expected by End of April
Mar 31, 2023 07:30 am ET
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
PRINCETON, N.J., March 31, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2022.
Mar 09, 2023 06:30 am ET
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request
Feb 14, 2023 06:30 am ET
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval
Feb 09, 2023 06:30 am ET
Soligenix Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023
Jan 19, 2023 06:30 am ET
Soligenix Invited to Present at the Virtual Investor Summit Event
Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market
Dec 23, 2022 03:01 pm ET
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
PRINCETON, N.J., Dec. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Standard Time on January 3, 2023. The shares of Series D Preferred Stock w
Dec 20, 2022 06:30 am ET
Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge
RiVax®-Vaccinated NHP survival was statistically significantly correlated with an epitope-specific serum assay ("EPICC") prior to challengeCorrelates of protection are essential to support approval via the FDA "Animal Rule"PRINCETON, N.J., Dec. 20, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of preclinical immunogenicity challenge studies for RiVax® (heat stable ricin toxin vaccin
Dec 19, 2022 06:30 am ET
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
Study HPN-PSR-01 opens patient enrollment
Dec 15, 2022 06:30 am ET
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Dec. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it submitted a new drug application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for HyBryte™ (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer and area of unmet medical need affecting over 25,000 patients in the U.S. The Company estimates the
Nov 15, 2022 06:30 am ET
Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Nov. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program. As a result, the Company anticipates being able to transfer this credit and receive approximately $1.2 million in net proceeds.
Nov 11, 2022 09:30 am ET
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference
Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summit live in NYC at the Sheraton Times Square. Jonathan Guarino, the Company's Senior Vice President and Chief Financial Officer, will be presenting a Company update and attend 1x1 meetings. During the presentation Mr. Guarino will highlight the Company's upcoming milestones including the filing of the new drug application with the U.S. Food and Drug Administration for HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma, a rare cancer. The presentation will be webcast and an archived recording will be made available in the Investor events section of the Soligenix website.
Nov 10, 2022 06:30 am ET
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
PRINCETON, N.J., Nov. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2022.
Nov 07, 2022 09:30 am ET
New to The Street Announces Five Corporate Interviews on Episode #404, Airing on the Fox Business Network, Tonight, Monday, November 7, 2022, at 10:30 PM PT
New to The Street, a nationally syndicated TV show, announces airing its episode #404 on the Fox Business Network tonight, Monday, November 7, 2022, at 10:30 PM PT. New to The Street’s 404th TV episode features the following five (5)...
Oct 27, 2022 07:30 am ET
Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
Emerging infectious diseases where no protective vaccines are currently available SuVax™ targets Sudan ebolavirus, origin of a current disease outbreak in UgandaPRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company has been invited by the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear
Oct 25, 2022 07:30 am ET
Soligenix Announces Formation of Psoriasis Medical Advisory Board
Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022
Oct 24, 2022 09:30 am ET
New to The Street TV Announces its 399th Show, Featuring Five Corporate Interviews, Airing on the Fox Business Network, Tonight, Monday, October 24, 2022, at 10:30 PM PT
FMW Media's New to The Street, a nationally syndicated TV show, announces episode #399 airing tonight, Monday, October 24, 2022, at 10:30 PM PT on the Fox Business Network. New to The Street’s 399th TV episode airs tonight, featuring the following...
Oct 21, 2022 09:30 am ET
New to The Street / Newsmax TV Announces its Nine Corporate Interviews for This Week's TV Broadcast, Episode #398, October 23, 2022, 10-11 AM ET
FMW Media's New to The Street / Newsmax TV announces the broadcasting line-up of its nationally syndicated 1-hour TV show this Sunday, October 23, 2022, airing time 10-11 AM ET. New to The Street's 398th TV episode line-up features nine...
Oct 20, 2022 08:30 am ET
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern TimeSoligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to vote by 11:59 p.m., Eastern Time on November 16, 2022PRINCETON, N.J., Oct. 20, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2022 Annual Meeting of Stockholders (the "Annual Meeting") has been further adjourned with respect to P
Oct 17, 2022 10:16 am ET
UPDATE: New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
FMW Media Inc.'s New to The Street is pleased to announce that Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,...
Oct 17, 2022 08:30 am ET
New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
FMW Media Inc.'s New to The Street is pleased to announce that Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,...
Sep 23, 2022 07:30 am ET
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
- Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time
Sep 12, 2022 08:30 am ET
FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL
New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryte™ treatment, including at-home usage. The FDA's support will give patients an opportunity to access Soligenix's HyBryte™ therapy in an open-label setting. HyBryte is a novel skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin disease and cancer.
Sep 08, 2022 07:30 am ET
Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRINCETON, N.J., Sept. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The conference will be held September 12 through 14, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Monday, September 12 at 7AM ET. The
Sep 06, 2022 07:30 am ET
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Grant supports study of expanded HyBryte™ treatment, including in the Home Use Setting
Aug 16, 2022 07:00 am ET
Presenting on the Emerging Growth Conference on August 17 Register Now
EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 37th Emerging Growth Conference. The Emerging...
Aug 12, 2022 07:30 am ET
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
PRINCETON, N.J., Aug. 12, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2022.
Jul 27, 2022 07:30 am ET
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., July 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received agreement from the US Food & Drug Administration (FDA) on an initial pediatric study plan (iPSP) for HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The agreed iPSP stipulates that Soligenix intends on requesting a full waiver of pediatric studies upon submissio
Jul 26, 2022 09:27 am ET
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients
HyBryte(TM) NDA Anticipated in H2 2022
Jul 25, 2022 07:30 am ET
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
SERB Pharmaceuticals pursuing therapeutic treatment against ricin poisoning using Soligenix ricin antigen
Jul 20, 2022 11:17 am ET
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
Published findings demonstrate that HyBryte™ treatment statistically significantly reduced CTCL lesion sizeHyBryte™ has potential to address a critical gap in treatment of early-stage CTCLPRINCETON, N.J., July 20, 2022 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results of its successful Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating HyBryte™ (synthetic h
Jun 28, 2022 07:30 am ET
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Enrollment on Track to Begin in 4th Quarter of 2022
Jun 23, 2022 07:30 am ET
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Bivalent vaccine provides 100% protection in non-human primates against both Sudan ebolavirus and Marburg marburgvirusOnly subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and Marburg virusesPRINCETON, N.J., June 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (NHPs) against lethal Marburg marburgvirus (MARV) challenge
Jun 07, 2022 08:30 am ET
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
Strategy supports global need and has potential use in growing home healthcare market
Jun 03, 2022 08:00 am ET
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an...
Jun 01, 2022 07:30 am ET
Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
Paper published in the Journal Structure
May 23, 2022 07:30 am ET
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
Includes thermostabilized Ebola vaccines Includes nanoemulsion adjuvant compatible with lyophilizationPRINCETON, N.J. , May 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The allowed claims are
May 18, 2022 07:30 am ET
Soligenix to Present at the H.C. Wainwright Global Investment Conference
PRINCETON, N.J., May 18, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright Global Investment Conference. The conference will be held May 23 through 26, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Tuesday, May 24 at 7AM ET. To view the presentation, pl
May 13, 2022 07:30 am ET
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
PRINCETON, N.J., May 13, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2022.
Apr 19, 2022 07:30 am ET
Soligenix Receives $1.4M in Non-Dilutive Government Funding
PRINCETON, N.J., April 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $1.4 million, net of transaction costs, in non-dilutive funding via multiple government tax programs.
Mar 29, 2022 07:30 am ET
Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results
PRINCETON, N.J., March 29, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2021.
Mar 17, 2022 07:30 am ET
Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
CiVax™ booster vaccine administered seven months after primary vaccination with COVID-19 adenovirus vaccine shows rapid enhancement of neutralizing antibody responses in non-human primates Neutralizing antibodies against Delta and original strain increased by up to 27-fold within one week and up to 243-fold within three weeks Omicron neutralizing antibody levels were undetectable prior to booster vaccination, and attained presumed protective levels within one week of vaccination PRINCETON, N.J., March 17, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late
Mar 02, 2022 08:45 am ET
SG Blocks, Inc. Leads Round of Investment for Moliving, Inc.
SG Blocks, Inc. (NASDAQ: SGBX) (“SG Blocks” or the “Company”), a leading developer, designer, and fabricator of modular structures, and Moliving Inc., the world’s first luxury nomadic hospitality solution, today announced SG Blocks is leading Moliving’s seed round. Moliving, which is a developer's solution conceived to disrupt the modular living and hospitality industries, offers hoteliers and landowners the opportunity to adjust room inventory to match demand in real time with minimal disruption to the environment.
Mar 02, 2022 06:30 am ET
Soligenix to Present at the Q1 Virtual Investor Summit
PRINCETON, N.J., March 2, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Financial Officer, Jonathan Guarino, has been invited to attend the Q1 Virtual Investor Summit. The conference will take place March 8-9, 2022, and includes one-on-one meetings and a Company presentation with Q&A at 1:15 P.M. EST on Tuesday, March 8, 2022. The presentation will
Mar 01, 2022 03:04 pm ET
Soligenix, Inc. to Present at the Q1 Virtual Investor Summit
Princeton, New Jersey--(Newsfile Corp. - March 1, 2022) - Soligenix, Inc. (NASDAQ: SNGX) today announced that Jonathan Guarino, Senior Vice President & Chief Financial Officer will be attending the Q1 Virtual Investor Summit. During the presentation, Soligenix’s Senior Vice President & Chief Financial Officer, Jonathan Guarino, will review the Company's robust pipeline and highlight upcoming potential value drivers, including an NDA filing to the FDA later this year. The presentation will be webcast and an archived recording will be made available in Investor Events section of the Soligenix website.
Feb 08, 2022 06:30 am ET
Soligenix to Present at the 2022 BIO CEO & Investor Conference
PRINCETON, N.J., Feb. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Conference taking place February 14-17, 2022. The presentation will be available to registered conference attendees for on-demand viewing beginning February 11, 2022 via the event
Jan 12, 2022 12:00 pm ET
Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)
New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good news for their shareholders. Despite supply-chain delays in receiving the active pharmaceutical ingredient for SGX301, aka HyBryte™, the company is still on track to file a new drug application with the FDA in the latter half of 2022.
Jan 10, 2022 06:30 am ET
Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts
PRINCETON, N.J., Jan. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Jan 06, 2022 06:30 am ET
Soligenix to Present at Upcoming Investor Conferences
PRINCETON, N.J., Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming virtual investor conferences below.
Jan 04, 2022 09:46 am ET
Thinking about buying stock in Genprex, TherapeuticsMD, Soligenix, Norwegian Cruise Line, or Zomedica?
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNPX, TXMD, SNGX, NCLH, and ZOM.
Jan 04, 2022 06:30 am ET
Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
PRINCETON, N.J., Jan. 4, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that dusquetide is effective at reducing tumor size in nonclinical xenograft models. Recent studies, recapitulating results from previously published studies, have confirmed the efficacy of dusquetide as a stand-alone and combination anti-tumor therapy, with radiation, chemotherapy and targeted therapy, in the context of the
Dec 02, 2021 06:30 am ET
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
PRINCETON, N.J., Dec. 2, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus (SUDV) challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This milestone is part of an ongoing collaboration with the University of Hawaiʻi at Mānoa (UHM), demons
Nov 30, 2021 08:30 am ET
Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers
New York, New York--(Newsfile Corp. - November 30, 2021) - PCG Digital -- Proof of concept in the biopharmaceutical sector is a process. Efficacy tests are performed, results are recorded from each round of clinical trials, and formulation changes are made if necessary. Each iteration moves the treatment closer to an NDA filing, with an end goal of achieving FDA approval. The goal is to gather enough data during trials to make that happen. Sometimes, you get more than what you're looking for. That's what happened with Soligenix (NASDAQ: SNGX) during their clinical trials of SGX301 (HyBryte™), a treatment option for cutaneous T-cell lymphoma (CTCL). Their research into using visible fluorescent light to activate synthetic hypericin to treat CTCL plaques and lesions has uncovered a potential treatment option for psoriasis.
Nov 12, 2021 06:30 am ET
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
PRINCETON, N.J., Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2021.
Nov 08, 2021 06:30 am ET
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a Pediatric Investigation Plan (PIP) product-specific waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for HyBryte™ (SGX301 or synthetic hypericin), which has successfully concluded a Phase 3 pivotal clinical study for the treatment of early stage cutaneous T-cell lymphoma (
Nov 04, 2021 07:30 am ET
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
PRINCETON, N.J., Nov. 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for RiVax® (heat stable ricin toxin vaccine) demonstrating enduring protection for at least 12 months post-vaccination. The article titled "Durable Immunity to Ricin Toxin Elicited by a Thermostable, Lyophilized Subunit Vaccine" has been accepted for publication in the journ
Nov 01, 2021 07:30 am ET
Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development
PRINCETON, N.J., Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Chief Scientific Officer, will be presenting key data from the Company's thermostable vaccine technology platform, including results from the Company's programs for ricin toxin vaccine (RiVax®), COVID-19 vaccine (CiVax™) and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses). The
Oct 13, 2021 08:30 am ET
Highlights and Insights into Soligenix
Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized Vaccines
Oct 12, 2021 07:30 am ET
HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit
PRINCETON, N.J., Oct. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today their poster abstract was selected as a "top abstract winner" and has been accepted for display and presentation at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit to be held virtually on October 18-19, 2021. Christopher Pullion, DO, Soligenix's Medical Director
Oct 07, 2021 08:30 am ET
Vaccine from Soligenix Could Accelerate Global Recovery from COVID-19 Pandemic
COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta Variants
Sep 28, 2021 07:30 am ET
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern. The article, titled "Protein Vaccine Induces a Durable, More Broadly Neutralizi
Sep 27, 2021 07:30 am ET
Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference
PRINCETON, N.J., Sept. 27, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will participate in a fireside chat hosted by Kristen Kluska, Director, Equity Research, at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00AM ET. In addition to the fireside chat, Dr. Schaber will be ava
Sep 16, 2021 07:30 am ET
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
PRINCETON, N.J., Sept. 16, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that following the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), as well as positive proof-of-concept (PoC) demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis p
Sep 14, 2021 08:30 am ET
Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics
Soligenix discusses its contribution to addressing future serious public health threats in a podcast
Sep 09, 2021 08:30 am ET
Thinking about buying stock in Torrid Holdings, Cardiff Oncology, Soligenix, Gold Royalty, or Enveric Biosciences?
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CURV, CRDF, SNGX, GROY, and ENVB.
Sep 09, 2021 07:30 am ET
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
PRINCETON, N.J., Sept. 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted.
Aug 24, 2021 08:30 am ET
Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Vaccines are known for the stringent cold chain storage requirements necessary to maintain their integrity. In the U.S., maintaining refrigerated or frozen conditions is a simple logistical hurdle. In developing nations, however, vaccine storage is a considerable challenge for the nearly three billion people who live in regions lacking temperature-controlled storage. As new vaccines are engineered, the development of thermally stable vaccines has lagged.
Aug 23, 2021 07:30 am ET
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens) combinations of filovirus vaccine candidates. In collaboration with University of Hawaiʻi at Mānoa (UHM) and University of Colorado (UC) co-authors, th
Aug 18, 2021 08:52 am ET
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines in a single vial platform presentation. Collaborators at the at the University of Hawaiʻi at Mānoa (UHM) describe the potent efficacy of vaccine candidates protecting against three life
Aug 13, 2021 07:30 am ET
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results
PRINCETON, N.J., Aug. 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2021.
Jul 29, 2021 08:30 am ET
Who Is Preparing Us for the Next Potential Pandemic?
New York, New York--(Newsfile Corp. - July 29, 2021) - -- PCG Digital -- Dr. Fauci said it publicly this week, but we've all been thinking it for months now. COVID-19 did not hit us, "out of the blue." Scientists, medical professionals, and researchers have been expecting this for years. The global pandemic was no surprise to them.
Jul 22, 2021 08:30 am ET
HyBryte(TM): Addressing an Unmet Need for Rare Lymphoma
Soligenix Demonstrates Clinical Success in First-in-Class Treatment for Cutaneous T-Cell Lymphoma
Jul 08, 2021 11:20 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.
Jul 06, 2021 03:39 pm ET
Shining a Light on a New Hope for a Rare Form of Non-Hodgkins Lymphoma: Conversation with Dr. Ellen Kim on HyBryte™ from Soligenix
via NewMediaWire -- PCG Digital -- A rare form of non-Hodgkin’s lymphoma, cutaneous T-cell lymphoma (CTCL) has no current FDA-approved first-line therapies. There are roughly 3,000 new CTCL cases in the United States each year, with more than...
Jun 23, 2021 09:35 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event.
Jun 22, 2021 07:30 am ET
HyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting
PRINCETON, N.J., June 22, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), w
Jun 10, 2021 08:30 am ET
Thinking about buying stock in Irving Resources, Soligenix, Exela Technologies, Soleno Therapeutics, or Onconova Therapeutics?
NEW YORK, June 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IRV, SNGX, XELA, SLNO, and ONTX.
Jun 10, 2021 07:30 am ET
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency
PRINCETON, N.J., June 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received a Pediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for HyBryte™ (SGX301 or hypericin), which has recently and successfully concluded a Phase 3, pivotal clinical study for the treatment of early stage cutaneous T-cell lymphoma (CTCL).
Jun 09, 2021 07:30 am ET
Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., June 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $865,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program.
Jun 03, 2021 08:30 am ET
Shining a Light on Soligenix's HyBryte(TM) Growth Opportunity
Company Connecting the Dots for Final FDA Approval
Mar 16, 2021 08:30 am ET
Soligenix Anticipated to Achieve Multiple Milestones in 2021
New York, New York--(Newsfile Corp. - March 16, 2021) - PCG Digital -- The future is looking bright at Soligenix, Inc. In a corporate update released on February 24th, Dr. Christopher Schaber, Chairman, President and CEO, updated investors on the status of ongoing research projects. The report suggests that multiple milestones will be achieved this year and next.
Feb 24, 2021 06:00 am ET
Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
PRINCETON, N.J., Feb. 24, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Feb 23, 2021 08:30 am ET
Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track
New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SNGX) is fast approaching a new drug application (NDA) submission and potential FDA approval for SGX301 (synthetic hypericin), a photodynamic treatment option to battle the debilitating effects of cutaneous T-Cell lymphoma (CTCL).
Feb 16, 2021 07:31 am ET
Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN.
Feb 11, 2021 06:00 am ET
Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference
PRINCETON, N.J., Feb. 11, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Digital Conference taking place February 16-18, 2021. The presentation will be available to registered conference attendees for on-demand viewing beginning February 15, 2021 at 9:
Feb 09, 2021 08:30 am ET
Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL).
Feb 01, 2021 06:00 am ET
Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Registrar of Patents has granted a patent for the application titled "Formulations and Methods of Treatment of Skin Conditions" (No. 16102842.8), published on January 29, 2021 under Publication No. 1214771 B. The granted claims are directed to the therapeutic use of synthetic hypericin in the tre
Jan 25, 2021 08:30 am ET
Soligenix Poised to Announce US Commercialization Plans of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatments for unmet medical needs has become increasingly important as the world continues to battle through the worst pandemic in our lifetime. While the news and focus of health innovation continues to be largely on COVID-19, medical breakthroughs continue to progress across the board.
Jan 19, 2021 06:00 am ET
Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be hosting an Investor Webcast Event on Tuesday, January 26, 2021 from 2:30-4:00 PM Eastern Standard Time (EST) regarding United States (U.S) commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL).
Jan 07, 2021 06:00 am ET
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed an exclusive Supply, Distribution and Services Agreement with Daavlin. Securing long-term supply and distribution of a commercially ready light device is an integral component of the regulatory and commercial strategy for SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL).
Dec 28, 2020 06:00 am ET
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Soligenix a Direct to Phase II Small Business Innovation Research (SBIR) grant of approximately $1.5 million to support manufacture, formulation (including thermostabilization) and characteriz
Dec 22, 2020 05:30 am ET
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results for its pivotal Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity) trial evaluating SGX942 (dusquetide) in the treatment of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) receiving chemoradiation. The study enrolled 268 patients
Dec 16, 2020 08:00 am ET
Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing
PRINCETON, N.J., Dec. 16, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has entered into a $20 million convertible debt financing agreement with Pontifax Medison Debt Financing (Pontifax), the healthcare-dedicated venture and debt fund of the Pontifax life science funds.
Dec 08, 2020 07:00 am ET
Soligenix Demonstrates Extended Protection with its RiVax® Ricin Toxin Vaccine
PRINCETON, N.J., Dec. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has demonstrated extended protection with its heat stable ricin toxin vaccine, RiVax®. Mice, vaccinated twice on Days 1 and 21 were protected for at least 365 days against subsequent ricin challenge. These results demonstrate that the thermostabilized vaccine formulation is capable of eliciting enduring protect
Nov 17, 2020 08:00 am ET
Pfizer and Moderna COVID-19 Vaccine Candidates Are Promising, but Soligenix's Civax (TM) May Be a Better Alternative
New York, New York--(Newsfile Corp. - November 17, 2020) - Enthusiasm is surrounding Pfizer's and Moderna's announcement of COVID-19 vaccine candidates that may soon become ripe for approval. But, in all fairness to the progress, tempering some of the excitement is warranted.
Nov 12, 2020 07:40 am ET
Soligenix, Inc. to Present at the virtual Fall Investor Summit on November 16th-18th
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Soligenix, Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.
Nov 12, 2020 06:00 am ET
Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results
PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2020.
Nov 10, 2020 06:00 am ET
Soligenix Invited to Present at Upcoming Virtual Investor Conferences
PRINCETON, N.J., Nov. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the upcoming virtual investor conferences below.
Oct 22, 2020 09:00 am ET
Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Oct. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued optional treatment with SGX301 (synthetic hypericin) across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH (Fluorescent Light Activated Synthet
Sep 21, 2020 08:30 am ET
Soligenix's RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White House
New York, New York--(Newsfile Corp. - September 21, 2020) - Soligenix's (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send ricin-laced letters to the White House last week raised fresh concerns about the deadly toxin. Those letters, including others addressed to Texas law enforcement agencies, were intercepted before delivery on Thursday. That news helped focus attention toward Soligenix's RiVax® program, which is considered the leading ricin-poisoning vaccine program in the world to protect against exposure to this deadly substance.
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies Set to Present - this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 28, 2020 09:31 am ET
Thinking about buying stock in Soligenix Inc, Trip.com Group, Boxlight Corp, Trevena Inc, or Aurora Cannabis?
NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, TCOM, BOXL, TRVN, and ACB.
Jul 28, 2020 07:00 am ET
Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine
PRINCETON, N.J., July 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for its CiVax™ program (heat stable COVID-19 vaccine), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HT™ (CoVaccine) adjuvant. The article, authored by collaborators at the University of Hawai
Jul 20, 2020 07:00 am ET
Soligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020
PRINCETON, N.J., July 20, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Jun 26, 2020 09:31 am ET
Thinking about buying stock in Soligenix Inc, Ekso Bionics, SINTX Technologies, AIM ImmunoTech, or Nio Inc?
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, EKSO, SINT, AIM, and NIO.
Jun 24, 2020 07:00 am ET
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis
PRINCETON, N.J., June 24, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its Phase 3 DOM-INNATE ("Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity") study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients. The study successfully enrolled 268 subjects, following positive interim anal
Jun 22, 2020 07:00 am ET
Soligenix to Join Russell Microcap® Index
PRINCETON, N.J., June 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29th, according to a final list of additions posted June 15th.
Jun 09, 2020 07:00 am ET
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference
PRINCETON, N.J., June 9, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Scientific Officer, Oreola Donini, PhD, will deliver a presentation discussing Soligenix's vaccine efforts, including a COVID-19 vaccine development program, at the MedInvest Infectious Disease and Immunology Investor Conference, held virtually on June 15 and 16, 2020.
May 15, 2020 07:00 am ET
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
PRINCETON, N.J., May 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2020.
May 11, 2020 07:00 am ET
Soligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine
PRINCETON, N.J., May 11, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of immunogenicity studies for RiVax® (heat stable ricin toxin vaccine) identifying novel correlates of immune protection to facilitate potential approval under the United States Food and Drug Administration (FDA) "Animal Rule." The article, titled "A Multivariate Model Combining Endpoint and Epitope-specific Ant
May 07, 2020 07:00 am ET
Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., May 7, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $840,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program.
Apr 30, 2020 07:00 am ET
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
PRINCETON, N.J., April 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued treatment with SGX301 (synthetic hypericin) twice weekly for 12 weeks increased the positive response rate to 40% (p<0.0001 compared to placebo and p<0.0001 compared to 6-weeks treatment) in the open-label treatment cycle (referred to as Cycle 2) of its pivotal Phase 3 FLASH (Fluorescent Li
Apr 16, 2020 07:00 am ET
Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals
PRINCETON, N.J., April 16, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has executed an agreement for the exclusive worldwide license of CoVaccine HT™, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals ("BTG"), a division of Boston Scientific Corporation (NYSE: BSX), for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu.
Apr 06, 2020 07:00 am ET
Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
PRINCETON, N.J., April 6, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European patent office has granted the divisional patent application titled "Formulations and Methods of Treatment of Skin Conditions" (No. 2932973). The granted claims are directed to the therapeutic use of synthetic hypericin in the treatment of cutaneous T-cell lymphoma (CTCL). Synthetic hypericin is the activ
Mar 30, 2020 07:00 am ET
Soligenix Announces Recent Accomplishments And Year-End 2019 Financial Results
PRINCETON, N.J., March 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2019.
Mar 24, 2020 09:11 am ET
Soligenix Inc. Heat-Stabilization Platform Evaluating Use With COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
New York, New York--(Newsfile Corp. - March 24, 2020) - Soligenix Inc. (NasdaqGS: SNGX), through its Public Health Solutions business segment, announced on Monday that the company is expanding its ongoing collaboration with the University of Hawai'i at Manoa to assess potential coronavirus vaccines, including COVID-19. More specifically, the study is evaluating the application of the company's heat-stabilization technology that has the potential to substantially alleviate the strains of cold-storage and distribution challenges associated with vaccines that need to progress quickly through supply channels. The heat-stabilization technology has demonstrated the feasibility of developing heat-stable subunit filovirus vaccines, including the Ebola virus disease caused by either Zaire or Sudan ebolavirus variants, as well as Marburg virus disease, with both monovalent and bivalent vaccine combinations.
Mar 23, 2020 07:00 am ET
Soligenix and University of Hawaiʻi at Mānoa Initiate Work on Novel Coronavirus Vaccine for COVID-19
PRINCETON, N.J., March 23, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its ongoing collaboration with the University of Hawaiʻi at Mānoa (UH Mānoa) is being expanded to assess potential coronavirus vaccines (including COVID-19).
Mar 20, 2020 08:37 am ET
Soligenix, Inc. Impresses With Statistically Significant Topline Phase 3 Data From SGX301 FLASH Trial; Targets $250 Million CTCL Patient Market
New York, New York--(Newsfile Corp. - March 20, 2020) - Soligenix, on Thursday, announced positive topline data for its lead CTCL drug candidate, SGX301. The published data demonstrated statistically significant efficacy results in treating this challenging and often debilitating chronic cancer. Additionally, this potentially transformative milestone for Soligenix (NASDAQ: SNGX) positions the company to explore strategic partnership and commercialization opportunities to take advantage of what is an expected $250 million drug market opportunity.
Mar 19, 2020 06:00 am ET
Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., March 19, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive preliminary top-line results for its pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial evaluating SGX301 (Synthetic Hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients randomized 2:1 to receive either SGX301 or placebo, demonstrating statisti
Feb 20, 2020 08:49 am ET
Independent Case Study For Soligenix's CTCL Drug, SGX301, Drives Bullish Sentiment; Topline "FLASH" Trial Data Expected Q1 2020
Miami Beach, Florida--(Newsfile Corp. - February 20, 2020) - Soligenix may be nearing a transformative point in its history as data from its Phase 3 SGX301 (FLASH) trial to treat cutaneous T-cell lymphoma (CTCL) nears its release. The topline data from this late-stage study is expected in less than 40 days. And, if that release can validate data known from a recent case study performed by Dr. Brian Poligone, MD, Ph.D., then Soligenix (NASDAQ: SNGX) may earn the first of several potential catalysts that can drive shareholder value higher.
Jan 30, 2020 08:12 am ET
Soligenix Stock Jumps 95% YTD Ahead of Topline Data Release For SGX301; Targeting $250 Million Unmet Market Opportunity To Treat CTCL
Positive results, expected in Q1 2020, can position SGX301 as the first FDA-approved front-line therapy to treat Cutaneous T-cell Lymphoma (CTCL)
Jan 16, 2020 08:42 am ET
Soligenix Shares Power Higher Ahead of SGX301 Phase 3 Data Release; Projected $200 Million Revenue Opportunity For CTCL Drug
Soulstring Media spots a substantial value opportunity in Soligenix, Inc.; Two near-term Phase 3 data releases can seize upon a $400 million drug market opportunity
Dec 13, 2019 04:00 pm ET
CORRECTION FROM SOURCE: Major Milestones for Soligenix Bring 2019 to a Strong Close
New York, New York--(Newsfile Corp. - December 13, 2019) - This news release has been corrected to add legal disclaimers. As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ: SNGX) has achieved multiple milestones across the company's core focus areas. Two treatments in development to treat rare diseases and/or areas of unmet medical need are currently in Phase 3 studies. Additionally, the Public Health Solutions arm has grown to operate under a multi-million-dollar contract with the National Institutes of Health (NIH).
Dec 11, 2019 01:30 pm ET
Major Milestones for Soligenix Bring 2019 to a Strong Close
New York, New York--(Newsfile Corp. - December 11, 2019) - As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ: SNGX) has achieved multiple milestones across the company's core focus areas. Two treatments in development to treat rare diseases and/or areas of unmet medical need are currently in Phase 3 studies. Additionally, the Public Health Solutions arm has grown to operate under a multi-million-dollar contract with the National Institutes of Health (NIH).
Nov 12, 2019 06:00 am ET
Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results
PRINCETON, N.J., Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2019.
Nov 06, 2019 06:00 am ET
Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference
PRINCETON, N.J., Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Daniel P. Ring, Vice President of Business Development and Strategic Planning, will deliver a corporate presentation reviewing the Company's two Phase 3 clinical programs and pipeline at the 25th Annual BIO-Europe International Partnering Conference in Hamburg, Germany, Tuesday, November 12, 2019 at 10:45 AM GMT. The ev
Oct 24, 2019 07:00 am ET
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
PRINCETON, N.J., Oct. 24, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (US) Patent Office has allowed the divisional patent application titled "Systems and Methods for Producing Synthetic Hypericin". The allowed claims are directed to unique, proprietary methods to produce a novel, highly purified form of synthetic hypericin. Synthetic hypericin is the active pharmaceu
Oct 22, 2019 08:48 am ET
Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Release Can Change the CTCL and Oral Mucositis Treatment Landscape
Miami Beach, Florida--(Newsfile Corp. - October 22, 2019) - There are two things that developing biotechs need for success. First, they need a good drug. Second, they need cash to fund clinical trials. Soligenix has both (NASDAQ: SNGX). Combined, the two may offer Soligenix investors a near-term opportunity to enjoy the rewards of both an FDA approval and the subsequent commercial launch of at least two promising drugs, SGX301 and SGX942, each targeting unmet medical needs. And, perhaps the best part of the consideration is that Soligenix is expected to deliver its first potentially transformative catalyst during the first quarter of next year from its FLASH trial to treat cutaneous T-cell lymphoma.On the heels of that data release, though, Soligenix investors may benefit from a second potential catalyst from the company's DOM-INNATE trial that is evaluating the effect of SGX942 on head and neck cancer patients suffering from oral mucositis. Topline analysis for that Phase III trial is expected during the first half of 2020. Combined, Soligenix and its investor base may be positioned for at least two substantial catalysts during the next 6-9 months. Notably, the company's pipeline candidates has been complimented by a stream of positive news generated from both promising Phase II results and positive interim analyses from Phase III trials.
Oct 03, 2019 08:16 am ET
Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer
Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ: SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head and neck cancer, an unmet medical need. And, as the release date approaches, investors may be looking for any clue they can get as to how the drug is performing. That clue, incidentally, may have been provided by the independent Data Monitoring Committee (DMC), who recently recommended that Soligenix increase its patient enrollment by 70 patients to validate the trial's 90% statistical significance threshold. Keeping in mind that the DMC had the power to end the trial if it thought the data could not meet its endpoint, it instead asked that the trial sample be increased to maintain a 90% statistical power measurement. That news should be interpreted as good. After all, the DMC is not in the business to put patients at risk of adverse events.Soligenix's most recent announcement about the DOM-INNATE trial was published on August 28th, when they announced a positive recommendation from the DMC to continue enrollment in the company's ongoing Phase 3 trial targeting the treatment of oral mucositis in patients with head and neck cancer. The recommendation from the DMC piqued the interest of those following the study, with many interpreting the request as a clue to how SGX942 may be benefiting study patients. There is consensus on several fronts.
Oct 03, 2019 07:00 am ET
Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada
PRINCETON, N.J., Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation to review the Company's two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the Global Chinese Financial Forum (GCFF) Conference on Saturday, October 5, 2019 at 11:55 am Pa
Sep 16, 2019 07:00 am ET
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
PRINCETON, N.J., Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has appointed Daniel P. Ring as Vice President of Business Development and Strategic Planning, effective immediately. Mr. Ring has over 22 years of business development and commercial experience in the biopharmaceutical industry. In this new role, Mr. Ring will oversee the Company's global business development fu
Sep 11, 2019 07:00 am ET
Soligenix Appoints Jonathan Guarino as Chief Financial Officer
PRINCETON, N.J., Sept. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has appointed Jonathan Guarino, as its Senior Vice President and Chief Financial Officer. Mr. Guarino has over 20 years of diverse experience in the financial and strategic management of emerging growth and commercial companies, including in the life sciences industry. He has a proven track record and expertise in
Aug 29, 2019 07:00 am ET
Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference
PRINCETON, N.J., Aug. 29, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation to review upcoming potential milestones for the Company's two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the RHK Capital 2019 Disruptive Growth
Aug 28, 2019 07:00 am ET
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
PRINCETON, N.J., Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the company's Phase 3 "DOM–INNATE" study (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck
Aug 15, 2019 07:00 am ET
Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications
PRINCETON, N.J., Aug. 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH), has awarded Soligenix a Phase I Small Business Innovation Research (SBIR) of approximately $150,000 to support the evaluation of SGX942 (dusquetide) in pediatric indications. This award will facilitate
Aug 13, 2019 07:00 am ET
Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results
PRINCETON, N.J., Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2019.
Jul 31, 2019 07:00 am ET
Soligenix Announces Conference Presentations Demonstrating Formulations of Single and Multivalent Ebola Subunit Vaccines
PRINCETON, N.J., July 31, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that two posters outlining ongoing formulation efforts to develop a trivalent thermostabilized Ebola vaccine will be presented on Wednesday July 31 at the 2019 Colorado Protein Stability Conference in Breckenridge, CO.
Jul 29, 2019 07:00 am ET
Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract
PRINCETON, N.J., July 29, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has issued two patents, both titled "Topically Active Steroids for use in Radiation and Chemotherapeutics Injury" with the latest issuing October 24, 2018, following the expiration of the objection period as of July 24, 2019. The new patents (#2,373,160 and #2,902,031) claim use of oral becl
Jul 08, 2019 07:00 am ET
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
PRINCETON, N.J., July 8, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Ms. Diane L. Parks to its Board of Directors.
May 28, 2019 07:00 am ET
Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents
PRINCETON, N.J., May 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Soligenix will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of approximately $600,000 over 3 years.
May 14, 2019 07:00 am ET
Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results
PRINCETON, N.J., May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2019.
Apr 23, 2019 07:00 am ET
Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
PRINCETON, N.J., April 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Apr 18, 2019 07:00 am ET
Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer
PRINCETON, N.J., April 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has reached a significant milestone in the Phase 3 clinical study (the "DOM-INNATE" study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer (HNC). Patient enrollment is sufficient to support the planned interim efficacy analysis by the independent Data Monitoring Comm
Apr 15, 2019 07:00 am ET
Soligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., April 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $611,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program.
Apr 09, 2019 07:00 am ET
Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942
PRINCETON, N.J., April 9, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) agreed to the Company's Pediatric Investigation Plan (PIP) for SGX942 (dusquetide). It was also agreed that the Company may defer conducting the PIP until successful completion of its ongoing pivotal Phase 3 clinical study evaluating SGX942 a
Apr 04, 2019 07:00 am ET
Soligenix Receives US Patent for Dusquetide Related Analogs
PRINCETON, N.J., April 4, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the US Patent Office will issue the patent titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity" on April 9, 2019. The new patent (#10,253,068) claims composition of matter for novel innate defense regulator (IDR) analogs
Mar 26, 2019 07:00 am ET
Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results
PRINCETON, N.J., March 26, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2018.
Mar 18, 2019 07:00 am ET
Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC
PRINCETON, N.J., March 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that they will be presenting at the National Institutes of Health (NIH) – Commercialization Accelerator Program (CAP) "FeedForward Session" in Washington, DC on March 21, 2019. The NIH selected Soligenix's SGX942 (dusquetide) development program for the treatment of oral mucositis in head and neck cancer (HNC) patients as
Mar 11, 2019 07:00 am ET
Soligenix to Present at the Boston Oncology Investor Conference 2019
PRINCETON, N.J., March 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Thursday, March 14 at 5:35 PM ET. The event will take place at 28 State Street, Boston, MA.
Feb 11, 2019 06:00 am ET
Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
PRINCETON, N.J., Feb. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the allowance of a new United States (US) patent protecting its ricin toxin vaccine, RiVax®. The patent, titled "Multivalent Stable Vaccine Composition and Methods of making same", supports combination vaccines protecting against ricin intoxication as well as other toxins, such as those associated with anthrax.
Feb 07, 2019 06:00 am ET
Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate
PRINCETON, N.J., Feb. 7, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of a scientific article demonstrating the successful thermostabilization of an Ebola subunit vaccine candidate. The article titled, "Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide", is published in the European Journal of Pharmaceutics and Biopharmaceutics online a
Jan 23, 2019 05:00 am ET
Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs
PRINCETON, N.J., Jan. 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity." The newly issued patent claims composition of matter of innate defense regulator (IDR) analogs, expanding p
Dec 11, 2018 05:00 am ET
Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Dec. 11, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program. As a result, the Company anticipates being able to transfer this credit and receive approximately $611,000 in net proceeds by year end.
Dec 05, 2018 05:00 am ET
Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology
PRINCETON, N.J., Dec. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of a review article discussing the therapeutic applications of its innate immune modulator technology, including dusquetide (the active ingredient in SGX942), its lead clinical Innate Defense Regulator (IDR). The article entitled, "Targeting Innate Immunity to Treat Disease: Potential Therapeutic Applications",
Nov 14, 2018 08:55 am ET
Investor Expectations to Drive Momentum within GEE Group, GigaMedia, China XD Plastics Company, Soligenix, Energy Transfer LP, and Oil-Dri Corporation Of America — Discovering Underlying Factors of In
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GEE Group Inc. (NYSE:JOB), GigaMedia Limited (NASDAQ:GIGM), China XD...
Nov 12, 2018 05:00 am ET
Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland
PRINCETON, N.J., Nov. 12, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule. The presentation will be given at the upcoming Fourth International Conference on Vaccines Research & De
Nov 09, 2018 05:00 am ET
Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results
PRINCETON, N.J., Nov. 9, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the third quarter ended September 30, 2018.
Oct 15, 2018 06:00 am ET
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the Company's Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). Following its unblinded inter
Oct 04, 2018 06:00 am ET
Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit
PRINCETON, N.J., Oct. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been invited to present results from two of its development programs at National Organization for Rare Disorders' (NORD's) Rare Diseases and Orphan Products Breakthrough Summit on October 15-16, 2018 in Washington, DC.
Sep 13, 2018 06:00 am ET
NIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program
PRINCETON, N.J., Sept. 13, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institutes of Health (NIH) selected Soligenix's SGX942 (dusquetide) development program for the treatment of oral mucositis in head and neck cancer (HNC) patients as a Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Commercialization Accelerator Program (CAP) Phase II awa
Sep 05, 2018 06:00 am ET
Soligenix to Present at BioCentury's 25th Annual NewsMakers in the Biotech Industry
PRINCETON, N.J., Sept. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the 25th Annual NewsMakers in the Biotech Industry on Friday, September 7 at 11:30AM ET. The event will take place at the Millennium Broadway Hotel & Conference Center in New York, NY.
Sep 04, 2018 06:00 am ET
Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine
PRINCETON, N.J., Sept. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of extended stability studies for RiVax® showing up to 100% protection in mice even after 12 months storage at 40 degrees Celsius (104 degrees Fahrenheit), as well as the identification of a potential in vitro stability indicating assay, critical to adequately confirming long-term shelf-life of the vaccine. The
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.